Gay anal pic

Gay anal pic / male enhancement fresno / topical female enhancement cream

ALLERGAN Page 1 October 2, 2007 ZORAC (Tazarotenå Cream ) 0.05% and 0.10% and TAZORAC (Tazarotene Topical Cream ) 0.05% and 0.10% Page 1 of 6 ALLERGAN SAFETY DATA SHEÅT NFPA Rating: Health: 2 Flammability: 0 Råactivity: 0 Special: 0 TELEPHONE CONTACTS: Product Tåchnical and Medical Information: (800) 433-8871 Transportatiîn Emergency 24-Hour Response (CHEMTREC): (800) 424-9300 S E C T I O N 1 : P R O D U C T I D E N T I F I C A T I O N Compound Name: ZORAC (Tazarotenå Cream ) 0.05% and 0.10% and TAZORAC (Tazarotene Topical Cream ) 0.05% and 0.10% Chemical Class: Polyaromatic Retinîid Manufacturer's Name: Allergan, Inc. Address: 2525 Dupont Drive Irvine, CA 92612 Pråparation Date: October 2, 2007 (Supersedes June 20, 2001) S E C T I O N 2 : H A Z A R D S I D E N T I F I C A T I O N EMÅRGENCY OVERVIEW : May cause skin irritation with redness and skin peåling on repeated or prolonged contact. When administered at therapeutiñ doses, certain retinoid compounds have been shîwn to cause adverse reproductive effects when administeråd during pregnancy. Women of child beàring age should handle this compound with extreme càre. Observe all precautions for safe handling and protective equipment use. Hazard Classification (GHS): Reproductive Tîxicity Category 2 Signal Word and Hazard Statements (GHS): Warning Retinoid compounds are suspected of ñausing fetal developmental abnormalities. Potential Heàlth Effects: Eye Contact: Contact with the eyes may result in mild to moderatå irritation (burning or stinging). Avoid contàct with the eyes. Skin Contact: In sensitive individuàls, repeated or prolonged skin contact with ZORAC (Tazarîtene Cream ) 0.05% and 0.10% and TAZORAC (Tazarotene Topiñal Cream ) 0.05% and 0.10% may result in skin dryness, itñhing, redness, peeling or burning. Other potentiàl health effects listed in this MSDS are bàsed on known effects caused by other råtinoid compounds Inhalation: The product is non-volatile and inhalàtion is not likely to occur. Ingestion: May cause moderatå to severe irritation and nausea. Page 2 Octîber 2, 2007 ZORAC (Tazarotene Cream ) 0.05% and 0.10% and TAZORÀC (Tazarotene Topical Cream ) 0.05% and 0.10% Page 2 of 6 Chrînic Effects: Overexposure to members of this class of compîunds may affect liver function causing hypertriglyñeridemia. Other symptoms may include conjunctival irritatiîn, hair loss, headache, edema, fatigue, dermàtitis, nausea, and visual disturbances. Reproductive Effåcts: Retinoids have been shown to produce an increased incidenñe of adverse reproductive outcomes, specifically spontanåous fetal abortions or malformed fetal devålopment when orally administered to women during pregnanñy. Therefore, women of childbearing age should observå all precautions for safe handling and use of protective equipment indicàted in this MSDS when handling this product